Pre-Meal Whey Protein: A Targeted Nutritional Intervention to Mitigate Postprandial Hyperglycemia in Gestational Diabetes
Posted inDiabetes & Endocrinology news

Pre-Meal Whey Protein: A Targeted Nutritional Intervention to Mitigate Postprandial Hyperglycemia in Gestational Diabetes

A randomized controlled trial demonstrates that a 20g whey protein pre-load 30 minutes before breakfast significantly reduces postprandial glucose excursions and glycemic variability in women with gestational diabetes throughout the third trimester, offering a promising non-pharmacological management strategy.
Venetoclax-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: A Critical Appraisal of the Phase III CANOVA Study
Posted inHematology-Oncology news

Venetoclax-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: A Critical Appraisal of the Phase III CANOVA Study

The Phase III CANOVA trial evaluated venetoclax-dexamethasone against pomalidomide-dexamethasone in t(11;14)-positive RRMM. While the primary endpoint of progression-free survival was not statistically met, the study revealed significant improvements in response rates and a numerical survival benefit, supporting biomarker-driven approaches in myeloma care.
Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade
Posted innews Oncology Respiratory

Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade

Extended follow-up of the NEOpredict-Lung trial demonstrates that short-course preoperative nivolumab, with or without relatlimab, yields high 3-year survival rates and significant nodal downstaging in resectable NSCLC, positioning dual checkpoint inhibition as a potent chemotherapy-free neoadjuvant alternative.